Dovitinib - Novartis

Drug Profile

Dovitinib - Novartis

Alternative Names: CHIR-258; Dovitinib lactate; GFKI-258; Growth factor kinase inhibitor 258; TKI 258

Latest Information Update: 06 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Developer Academic and Community Cancer Research United; Case Comprehensive Cancer Center; Georgetown University; National Cancer Institute (USA); Novartis; Ontario Clinical Oncology Group; University of California, Davis; University of Texas M. D. Anderson Cancer Center; University of Virginia; Yonsei University Health System
  • Class Antineoplastics; Benzimidazoles; Lactates; Piperazines; Quinolones; Small molecules
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Platelet-derived growth factor beta receptor antagonists; Proto oncogene protein c-kit inhibitors; Type 3 fibroblast growth factor receptor antagonists; Vascular endothelial growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Adenoid-cystic-carcinoma
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Adenoid-cystic-carcinoma; Breast cancer; Colorectal cancer; Endometrial cancer; Gastric cancer; Gastrointestinal stromal tumours; Glioblastoma; Haematological malignancies; Hepatocellular carcinoma; Malignant melanoma; Mesothelioma; Multiple myeloma; Neuroendocrine tumours; Non-small cell lung cancer; Pancreatic cancer; Prostate cancer; Renal cancer; Solid tumours; Thyroid cancer; Urogenital cancer; Von Hippel-Lindau disease

Most Recent Events

  • 28 Jun 2018 The US FDA transfers Orphan Drug tag to Oncology Venture for the treatment of Adenoid cystic carcinoma
  • 09 Apr 2018 Dovitinib licensed to Oncology Venture worldwide
  • 09 Apr 2018 Oncology Ventures plans a phase II trial for Breast cancer and Liver cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top